or
forgot password

The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia


N/A
18 Years
N/A
Open (Enrolling)
Both
Chronic Myelomonocytic Leukemia

Thank you

Trial Information

The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia


Inclusion Criteria:



- Subject must be at least 18 years or older.

- Subject must sign informed consent.

- For study population only, the subject must have a CMML diagnosis based on the WHO
2009 criteria.

- For control population only, the subject must be deemed healthy with no hematologic
disorders.

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Principal Investigator

Peter Emanuel, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Arkansas

Authority:

United States: Institutional Review Board

Study ID:

111245

NCT ID:

NCT01010256

Start Date:

November 2009

Completion Date:

Related Keywords:

  • Chronic Myelomonocytic Leukemia
  • To evaluate the phosphate and tension homolog deleted on chromosome ten (PTEN) protein level in leukemia cells from patients with CMML.
  • To identify the PTEN genetic defect in patients with deficient PTEN protein levels.
  • To evaluate the role of PTEN deregulation in CMML pathogenesis.
  • Leukemia
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia, Myelomonocytic, Acute

Name

Location
University of Arkansas for Medical Sciences Little Rock, Arkansas  72205